Outlook Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell OTLK and other ETFs, options, and stocks.About OTLK
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF.
CEOLawrence A. Kenyon
CEOLawrence A. Kenyon
Employees23
Employees23
HeadquartersIselin, New Jersey
HeadquartersIselin, New Jersey
Founded2010
Founded2010
Employees23
Employees23
OTLK Key Statistics
Market cap100.83M
Market cap100.83M
Price-Earnings ratio-2.08
Price-Earnings ratio-2.08
Dividend yield—
Dividend yield—
Average volume2.38M
Average volume2.38M
High today$2.54
High today$2.54
Low today$2.24
Low today$2.24
Open price$2.49
Open price$2.49
Volume2.97M
Volume2.97M
52 Week high$3.39
52 Week high$3.39
52 Week low$0.79
52 Week low$0.79
Stock Snapshot
Outlook Therapeutics(OTLK) stock is priced at $2.26, giving the company a market capitalization of 100.83M. It carries a P/E multiple of -2.08.
On 2025-12-18, Outlook Therapeutics(OTLK) stock moved within a range of $2.24 to $2.54. With shares now at $2.26, the stock is trading +0.9% above its intraday low and -11.0% below the session's peak.
Trading activity shows a volume of 2.97M, compared to an average daily volume of 2.38M.
Over the past 52 weeks, Outlook Therapeutics(OTLK) stock has traded between a high of $3.39 and a low of $0.79.
Over the past 52 weeks, Outlook Therapeutics(OTLK) stock has traded between a high of $3.39 and a low of $0.79.
People also own
Based on the portfolios of people who own OTLK. This list is generated using Robinhood data, and it’s not a recommendation.